Listen to Medscape InDiscussion: Colorectal Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas...
S2 Episode 6: In Colorectal Cancer, Donating Half a Liver Could Save Lives
Join Drs Benjamin Schlechter and Martin Dib as they discuss cutting-edge transplant techniques to treat colorectal cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000094. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Colorectal Cancer: Prevention, Diagnosis, and Therapeutic Options https://reference.medscape.com/slideshow/colorectal-cancer-6007241 Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients With Cirrhosis https://pubmed.ncbi.nlm.nih.gov/8594428/ Chemotherapy and Liver Transplantation Versus Chemotherapy Alone in Patients With Definitively Unresectable Colorectal Liver Metastases: A Prospective Multicentric Randomized Trial (TRANSMET) https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3500 Safety and Feasibility of Chemotherapy Followed by Liver Transplantation for Patients With Definitely Unresectable Colorectal Liver Metastases: Insights From the TransMet Randomised Clinical Trial https://pubmed.ncbi.nlm.nih.gov/38721015/ Liver Transplantation for Hepatic Metastases From Colorectal Cancer: Current Knowledge and Open Issues https://pubmed.ncbi.nlm.nih.gov/36672295/ Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/23360920/ Survival Following Liver Transplantation for Patients With Nonresectable Liver-Only Colorectal Metastases https://pubmed.ncbi.nlm.nih.gov/31188200/ Carcinoembryonic Antigen https://www.ncbi.nlm.nih.gov/books/NBK578172/ BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies https://pubmed.ncbi.nlm.nih.gov/36077604/ Perioperative Management of the Patient With Liver Disease https://emedicine.medscape.com/article/284667-overview KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration https://pubmed.ncbi.nlm.nih.gov/36675641/ R0 Liver Resection Should Be a First-Line Treatment for Selected Patients With Intermediate Hepatocellular Cancer https://pubmed.ncbi.nlm.nih.gov/37408800/
-------- Â
26:25
S2 Episode 5: Adjuvant Chemo in Colorectal Cancer: What's Working Now?
Join Drs Benjamin Schlechter and Jeff Meyerhardt as they discuss the latest breakthroughs in adjuvant chemo for CRC and share their decision-making in real-world scenarios. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000093. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Colorectal Cancer: Prevention, Diagnosis, and Therapeutic Options https://reference.medscape.com/slideshow/colorectal-cancer-6007241 Colon Cancer https://emedicine.medscape.com/article/277496-overview Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer https://pubmed.ncbi.nlm.nih.gov/15175436/ Duration of Adjuvant Chemotherapy for Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/29590544/ Overall Survival With 3 or 6 Months of Adjuvant Chemotherapy in Italian TOSCA Phase 3 Randomised Trial https://pubmed.ncbi.nlm.nih.gov/33098997/ 3 Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Combination Therapy for Colorectal Cancer (SCOT): An International, Randomised, Phase 3, Non-Inferiority Trial https://pubmed.ncbi.nlm.nih.gov/29611518/ Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin as First-Line Therapy for Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/18421053/ Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials https://pubmed.ncbi.nlm.nih.gov/36306483/ Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database https://pubmed.ncbi.nlm.nih.gov/23733765/ Comparative Effectiveness of Oxaliplatin vs Non-Oxaliplatin-Containing Adjuvant Chemotherapy for Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/22266473/ Role of Physical Activity and Diet After Colorectal Cancer Diagnosis https://pubmed.ncbi.nlm.nih.gov/25918293/ Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer https://pubmed.ncbi.nlm.nih.gov/17699009/ Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone as Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 https://pubmed.ncbi.nlm.nih.gov/17687149/ Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II) https://pubmed.ncbi.nlm.nih.gov/35014958/
-------- Â
24:52
S2 Episode 4: The Evolution of Nonoperative Rectal Cancer Management
Join Drs Benjamin Schlechter and Joshua Smith as they discuss the evolution of nonoperative rectal cancer management and organ preservation, highlighting groundbreaking trials like OPRA and JANUS. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000092. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients With Locally Advanced Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/38712176/ Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-Term Results https://pubmed.ncbi.nlm.nih.gov/15383798/ Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial https://pubmed.ncbi.nlm.nih.gov/37883738/ Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) https://pubmed.ncbi.nlm.nih.gov/37270691/ Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial https://pubmed.ncbi.nlm.nih.gov/30192323/ Overall Survival After Treatment Failure Among Patients With Rectal Cancer https://pubmed.ncbi.nlm.nih.gov/37902752/ Short-Course Radiotherapy Followed by Chemotherapy Before Total Mesorectal Excision (TME) Versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33301740/ Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial https://pubmed.ncbi.nlm.nih.gov/36661037/ Neoadjuvant Chemotherapy With FOLFIRINOX and Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/33862000/ Phase III Trial of Short-Course Radiotherapy Followed by CAPOXIRI Versus CAPOX in Locally Advanced Rectal Cancer: The ENSEMBLE Trial https://www.esmogastro.org/article/S2949-8198(23)00003-1/fulltext
-------- Â
26:27
S2 Episode 3: How Do You Treat Refractory Colorectal Cancer?
Join Drs Benjamin Schlechter and Cathy Eng as they discuss the treatments and clinical trials available for patients with refractory colorectal cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000091. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/25970050/ Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/37133585/ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/23177514/ Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Asian Patients With Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/25981818/ Regorafenib Dose-Optimisation in Patients With Refractory Metastatic Colorectal Cancer (ReDOS): A Randomised, Multicentre, Open-Label, Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/31262657/ Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial https://pubmed.ncbi.nlm.nih.gov/33604969/ Fruquintinib Versus Placebo in Patients With Refractory Metastatic Colorectal Cancer (FRESCO-2): An International, Multicentre, Randomised, Double-Blind, Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/37331369/ Targeting KRAS in Cancer https://pubmed.ncbi.nlm.nih.gov/38637634/ Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/29946728/
-------- Â
21:59
S2 Episode 2: Young-Onset Colorectal Cancer: How Do We Move Forward?
Young-onset colorectal cancer is on the rise, challenging GI oncologists across the globe. Join Drs Benjamin Schlechter and Kimmie Ng as they share their expertise and experience. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000090. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines https://pubmed.ncbi.nlm.nih.gov/36549470/ DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations https://pubmed.ncbi.nlm.nih.gov/37992266/ Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/31243121/ Evaluation of Genomic Alterations in Early-Onset Versus Late-Onset Colorectal Cancer https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3511 Young Onset Colorectal Cancer Patients Are Diagnosed With Advanced Disease After Multiple Misdiagnoses https://aacrjournals.org/cancerres/article/79/13_Supplement/3347/635227/Abstract-3347-Young-onset-colorectal-cancer Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women https://pubmed.ncbi.nlm.nih.gov/30326010/ Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/30740587/ Sugar-Sweetened Beverage Intake in Adulthood and Adolescence and Risk of Early-Onset Colorectal Cancer Among Women https://pubmed.ncbi.nlm.nih.gov/33958435/ A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers https://pubmed.ncbi.nlm.nih.gov/34405229/ Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405 https://pubmed.ncbi.nlm.nih.gov/34636852/ Overtreatment of Young Adults With Colon Cancer: More Intense Treatments With Unmatched Survival Gains https://pubmed.ncbi.nlm.nih.gov/25806815/
Listen to Medscape InDiscussion: Colorectal Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/986437). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
South Africa